Team

12 Senior Operators. Zero Junior Associates.

Across investor & stakeholder communications, clinical development, regulatory affairs, commercial strategy, market access, corporate finance, M&A, and IPO.

Built to Guide Every Stage of the Biotech Journey

The Primary Decision Makers We Support: We are your third-party support team
Founder / CEO
CFO / Board
CMO / CSO
BD Lead
Investor / VC

Right-Sized for Your Stage

Strategic Advisory

Focused guidance, executive workshops, and leadership sessions to align stakeholders on critical decisions.

Fractional Embedded Leadership

Senior executive embedded within your team (e.g., Fractional CCO) to drive commercial execution without the overhead of a full-time hire.

Project Implementation

End-to-end project delivery with a defined scope, timeline, and deliverables. Ideal for indication prioritization, TPP development, or market sizing.

Bespoke Ongoing Support

Continuous advisory retainer tailored to evolving needs. Provides flexible access to our team's expertise as your company grows.

Biopharma companies do not need more adjectives. They need evidence-driven positioning that makes complex science understandable, credible, differentiated, and relevant to each audience.

Verify through Strategic AI Audit

Gain alignment among C Suite on organizations Goals, Challenges and unmet needs. Elect a sponsor to champion the assessment.

Before implementing any technology, good practice dictates a deep-dive Strategic Audit to assess readiness and commercial inflection points.

Data Rights & Provenance

Identifying available clinical and real-world datasets and their compliance status.

Use-Case Prioritization

Ranking opportunities by Commercial Materiality and probability of technical success.

Maturity Assessment

Evaluating current internal capabilities vs. required vendor infrastructure.

Risk Mapping

Defining legal, regulatory, and GxP constraints early in the process.

Commercialization readiness begins when a company can define who will use the product, why it will win, how it will be paid for, what adoption barriers exist, and which evidence will change medical practice.